Semaglutide's real-world effectiveness in Type 2 Diabetes to be assessed in Dutch clinical practice
Background
Managing Type 2 Diabetes (T2D) remains a significant challenge, with many patients struggling to achieve optimal glycemic control and manage associated comorbidities. While randomized controlled trials (RCTs) demonstrate the efficacy and safety of new treatments like GLP-1 receptor agonists (GLP-1RAs) such as semaglutide, real-world evidence is crucial. RCTs often involve highly selected patient populations and controlled environments, which may not fully reflect the diverse patient demographics, adherence patterns, and varied clinical settings encountered in everyday practice. Understanding how semaglutide performs in a broader, unselected patient population under typical care conditions is essential for informing clinical guidelines and optimizing patient outcomes.
Study Design
The SURE NETHERLANDS study is a multi-center, prospective, non-interventional study designed to collect real-world data on semaglutide effectiveness. Adult patients with Type 2 Diabetes in the Netherlands, for whom semaglutide is prescribed as part of their routine clinical care, will be enrolled. Participants will receive semaglutide as prescribed by their study doctor, with no specific intervention protocol dictated by the study beyond standard care. The study will last for approximately 6 to 8 months. Data collection will involve participants completing questionnaires about their health and diabetes treatment during their normally scheduled clinic visits, alongside the collection of relevant clinical data from their medical records. This design aims to observe outcomes without influencing treatment decisions.
Results
This study description outlines the purpose and methodology of the SURE NETHERLANDS trial, a prospective, non-interventional study designed to collect real-world data on semaglutide effectiveness. As an observational study protocol, it does not present specific efficacy or safety findings. The primary objective is to gather information on how semaglutide performs in a diverse patient population with Type 2 Diabetes under routine clinical practice in the Netherlands, focusing on patient-reported outcomes and treatment patterns over 6 to 8 months. The study aims to provide insights into the practical application and observed benefits of semaglutide in a real-world setting, complementing the controlled data from randomized clinical trials.
Key Findings
- No efficacy or safety findings are presented in this study description; it outlines the study's purpose and design.
Why It Matters
This real-world study is crucial for understanding semaglutide's effectiveness beyond controlled clinical trials, offering insights into its performance in diverse patient populations and varied clinical settings. Clinicians can gain valuable context on how semaglutide performs in patients with multiple comorbidities, varying adherence, and different lifestyle factors. This data can help refine prescribing patterns, manage patient expectations, and inform local treatment guidelines for Type 2 Diabetes. For individuals using or considering semaglutide, this research will provide a more realistic picture of potential outcomes in a non-idealized setting, addressing questions about its practical utility and long-term benefits in real-world scenarios. It bridges the gap between highly controlled research and everyday clinical practice, offering a more complete understanding of this important GLP-1 receptor agonist.
semaglutide
type-2-diabetes
real-world-evidence
observational-study
glycemic-control
netherlands